Drug Approval | February 18, 2023
Themis gets DCGI approval of Remifentanil Hydrochloride 1mg/2mg injection for import and marketing
Themis will market this drug with the brand name REMITHEM.
Themis will market this drug with the brand name REMITHEM.
According to GlobalData’s analyst consensus forecast, OTX-2002 is projected to have the highest revenue by 2028, with sales of $1.6 billion during that year
Durvalumab in combination with chemotherapy is indicated for the treatment of patients with locally advanced or metastatic biliary tract cancer
The company has launched its new range of 25 allopathy ophthalmic products including GUERIMOD, GUERIPRED, BIMATO MST etc. for curing various diseases related to eyes
The investment enhances Lonza’s capabilities and flexibility to support both clinical and commercial supply and will play a key role in meeting the growing market demand for bioconjugates
The Applied Biosystems TaqPath PCR kits have been analytically- and clinically-validated for use in patient care
Qure.ai is scaling-up the integration of its AI-powered chest x-ray interpretation tool that can benefit early and easy detection of lung diseases including lung cancer.
Through this collaboration, the erstwhile Government Maternity Hospital in Kanakapura Taluk has been rebuilt and the new hospital has facilities including oxygen and medical gas pipelines
Thermo Fisher and Celltrio bring first-in-kind automation platform to address critical scale-up challenges in biotherapeutics RoboCell cell line automation platform
Subscribe To Our Newsletter & Stay Updated
